Verona Pharma

Breath of Innovation®

Verona Pharma is developing life enhancing treatments for respiratory diseases.
November is COPD Awareness Month and World COPD Day.

November is COPD Awareness Month and World COPD Day. Verona Pharma is raising awareness of this serious unmet need along with the American Lung Association and Asthma + Lung UK. Find out more about these support groups here

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.

The unmet need


Cystic Fibrosis


Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Pulmonary Disease.

Find out more

Latest Film

Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD



© Verona Pharma plc 2022. All rights reserved